Ralph Venhaus
Publications by Year
Research Areas
Immunotherapy and Immune Responses, Cancer Immunotherapy and Biomarkers, CAR-T cell therapy research, vaccines and immunoinformatics approaches, Glioma Diagnosis and Treatment
Most-Cited Works
- → Vaccination with NY-ESO-1 protein and CpG in Montanide induces integrated antibody/Th1 responses and CD8 T cells through cross-priming(2007)295 cited
- → Phase I Trial of Overlapping Long Peptides from a Tumor Self-Antigen and Poly-ICLC Shows Rapid Induction of Integrated Immune Response in Ovarian Cancer Patients(2012)272 cited
- → Immunization of Malignant Melanoma Patients with Full-Length NY-ESO-1 Protein Using TLR7 Agonist Imiquimod as Vaccine Adjuvant(2008)244 cited
- → Phase I/II study of pegylated arginine deiminase (ADI-PEG 20) in patients with advanced melanoma(2012)145 cited
- → Regulatory T-Cell–Mediated Attenuation of T-Cell Responses to the NY-ESO-1 ISCOMATRIX Vaccine in Patients with Advanced Malignant Melanoma(2009)118 cited
- → Resiquimod as an Immunologic Adjuvant for NY-ESO-1 Protein Vaccination in Patients with High-Risk Melanoma(2015)91 cited
- → Phase II study to evaluate safety and efficacy of MEDI4736 (durvalumab) + radiotherapy in patients with newly diagnosed unmethylated MGMT glioblastoma (new unmeth GBM).(2019)52 cited
- → Immunoediting and persistence of antigen-specific immunity in patients who have previously been vaccinated with NY-ESO-1 protein formulated in ISCOMATRIX™(2011)49 cited
- → Phase 2 study to evaluate safety and efficacy of MEDI4736 (durvalumab [DUR]) in glioblastoma (GBM) patients: An update.(2017)49 cited
- → NY‐ESO ‐1 specific antibody and cellular responses in melanoma patients primed with NY‐ESO ‐1 protein in ISCOMATRIX and boosted with recombinant NY‐ESO ‐1 fowlpox virus(2014)48 cited